Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.
Reata (RETA) reports a wider-than-expected loss in the second quarter of 2022, while revenues miss estimates. Stock falls after updates on pipeline programs.
Puma Biotech (PBYI) beats earnings and revenue estimates in second-quarter 2022. PBYI's stock surges at market close following the news.